Quarterly ResultMay 11, 2026, 04:13 PM
Enanta Q2 Net Loss $13.1M, Revenue $17.2M; EDP-978 Phase 1 Dosing Initiated
AI Summary
Enanta Pharmaceuticals reported improved financial results for its fiscal second quarter ended March 31, 2026, with a reduced net loss of $13.1 million and increased revenue of $17.2 million. The company announced significant progress in its immunology pipeline, including the initiation of a Phase 1 trial for EDP-978 and being on track for key milestones for EPS-3903 and MRGPRX2. Enanta also continues enabling activities for a pivotal study of zelicapavir in RSV and expects its $227 million cash and marketable securities to fund operations into fiscal 2029, while also providing updates on its patent litigation against Pfizer.
Key Highlights
- Q2 2026 Net Loss: $13.1M, down from $22.6M in Q2 2025.
- Q2 2026 Total Revenue: $17.2M, up from $14.9M in Q2 2025.
- Q2 2026 R&D Expenses: $19.4M, down from $28.1M in Q2 2025.
- Cash, cash equivalents, and marketable securities: $227.0M at March 31, 2026.
- Cash runway expected to fund operations into fiscal 2029.
- Dosing initiated in Phase 1 trial of EDP-978 for chronic urticaria; topline data expected 4Q 2026.
- On track to file IND for EPS-3903 and select MRGPRX2 candidate in 2H 2026.
- Oral arguments held in Pfizer patent infringement lawsuit; decision expected by end of September 2026.